These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 34861783)

  • 21. Age-stratified adeno-associated virus serotype 3 neutralizing and total antibody prevalence in hemophilia A patients from India.
    Daniel HD; Kumar S; Kannangai R; J F; Joel JN; Abraham A; Lakshmi KM; Agbandje-McKenna M; Coleman KE; Srivastava A; Srivastava A; Abraham AM
    J Med Virol; 2022 Sep; 94(9):4542-4547. PubMed ID: 35577570
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mapping an Adeno-associated Virus 9-Specific Neutralizing Epitope To Develop Next-Generation Gene Delivery Vectors.
    Giles AR; Govindasamy L; Somanathan S; Wilson JM
    J Virol; 2018 Oct; 92(20):. PubMed ID: 30089698
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Determination of anti-adeno-associated virus vector neutralizing antibody titer with an in vitro reporter system.
    Meliani A; Leborgne C; Triffault S; Jeanson-Leh L; Veron P; Mingozzi F
    Hum Gene Ther Methods; 2015 Apr; 26(2):45-53. PubMed ID: 25819687
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Binding and neutralizing anti-AAV antibodies: Detection and implications for rAAV-mediated gene therapy.
    Schulz M; Levy DI; Petropoulos CJ; Bashirians G; Winburn I; Mahn M; Somanathan S; Cheng SH; Byrne BJ
    Mol Ther; 2023 Mar; 31(3):616-630. PubMed ID: 36635967
    [TBL] [Abstract][Full Text] [Related]  

  • 25. AAV Natural Infection Induces Broad Cross-Neutralizing Antibody Responses to Multiple AAV Serotypes in Chimpanzees.
    Calcedo R; Wilson JM
    Hum Gene Ther Clin Dev; 2016 Jun; 27(2):79-82. PubMed ID: 27314914
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Seroprevalence of Neutralizing Antibodies against Human Adenovirus Type-5 and Chimpanzee Adenovirus Type-68 in Cancer Patients.
    Zhao H; Xu C; Luo X; Wei F; Wang N; Shi H; Ren X
    Front Immunol; 2018; 9():335. PubMed ID: 29563911
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pre-existing anti-adeno-associated virus antibodies as a challenge in AAV gene therapy.
    Louis Jeune V; Joergensen JA; Hajjar RJ; Weber T
    Hum Gene Ther Methods; 2013 Apr; 24(2):59-67. PubMed ID: 23442094
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Utility of microminipigs for evaluating liver-mediated gene expression in the presence of neutralizing antibody against vector capsid.
    Watano R; Ohmori T; Hishikawa S; Sakata A; Mizukami H
    Gene Ther; 2020 Sep; 27(9):427-434. PubMed ID: 32066928
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neutralizing antibodies against AAV2, AAV5 and AAV8 in healthy and HIV-1-infected subjects in China: implications for gene therapy using AAV vectors.
    Liu Q; Huang W; Zhang H; Wang Y; Zhao J; Song A; Xie H; Zhao C; Gao D; Wang Y
    Gene Ther; 2014 Aug; 21(8):732-8. PubMed ID: 24849042
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Seroprevalence of Adeno-Associated Virus Neutralizing Antibodies in Males with Duchenne Muscular Dystrophy.
    Verma S; Nwosu SN; Razdan R; Upadhyayula SR; Phan HC; Koroma AA; Leguizamo I; Correa NS; Kuipa M; Lee D; Vanderford TH; Gardner MR
    Hum Gene Ther; 2023 May; 34(9-10):430-438. PubMed ID: 36324212
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical enrollment assay to detect preexisting neutralizing antibodies to AAV6 with demonstrated transgene expression in gene therapy trials.
    Cao L; Ledeboer A; Pan Y; Lu Y; Meyer K
    Gene Ther; 2023 Feb; 30(1-2):150-159. PubMed ID: 35778500
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prevalence of AAV1 neutralizing antibodies and consequences for a clinical trial of gene transfer for advanced heart failure.
    Greenberg B; Butler J; Felker GM; Ponikowski P; Voors AA; Pogoda JM; Provost R; Guerrero J; Hajjar RJ; Zsebo KM
    Gene Ther; 2016 Mar; 23(3):313-9. PubMed ID: 26699914
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preexisting Neutralizing Antibodies to Adeno-Associated Virus Capsids in Large Animals Other Than Monkeys May Confound In Vivo Gene Therapy Studies.
    Calcedo R; Franco J; Qin Q; Richardson DW; Mason JB; Boyd S; Wilson JM
    Hum Gene Ther Methods; 2015 Jun; 26(3):103-5. PubMed ID: 26067568
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ocular Inflammatory Response to Intravitreal Injection of Adeno-Associated Virus Vector: Relative Contribution of Genome and Capsid.
    Timmers AM; Newmark JA; Turunen HT; Farivar T; Liu J; Song C; Ye GJ; Pennock S; Gaskin C; Knop DR; Shearman MS
    Hum Gene Ther; 2020 Jan; 31(1-2):80-89. PubMed ID: 31544533
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevalence and pharmacological modulation of humoral immunity to AAV vectors in gene transfer to synovial tissue.
    Mingozzi F; Chen Y; Edmonson SC; Zhou S; Thurlings RM; Tak PP; High KA; Vervoordeldonk MJ
    Gene Ther; 2013 Apr; 20(4):417-24. PubMed ID: 22786533
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Step-By-Step Method to Detect Neutralizing Antibodies Against AAV using a Colorimetric Cell-Based Assay.
    Bass-Stringer S; Thomas CJ; May CN; Gregorevic P; Weeks KL; McMullen JR
    J Vis Exp; 2021 Dec; (178):. PubMed ID: 34958085
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gene Delivery of Activated Factor VII Using Alternative Adeno-Associated Virus Serotype Improves Hemostasis in Hemophiliac Mice with FVIII Inhibitors and Adeno-Associated Virus Neutralizing Antibodies.
    Sun J; Hua B; Chen X; Samulski RJ; Li C
    Hum Gene Ther; 2017 Aug; 28(8):654-666. PubMed ID: 28478688
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of viral dose on neutralizing antibody response and transgene expression after AAV1 vector re-administration in mice.
    Petry H; Brooks A; Orme A; Wang P; Liu P; Xie J; Kretschmer P; Qian HS; Hermiston TW; Harkins RN
    Gene Ther; 2008 Jan; 15(1):54-60. PubMed ID: 17960164
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Assessment of a passive immunity mouse model to quantitatively analyze the impact of neutralizing antibodies on adeno-associated virus-mediated gene transfer.
    Sun L; Tu L; Gao G; Sun X; Duan J; Lu Y
    J Immunol Methods; 2013 Jan; 387(1-2):114-20. PubMed ID: 23063691
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Efficient and durable gene delivery of self complementary adeno-associated virus 6 vector and impact of pre-existing immunity].
    Tu L; Sun L; Xue J; Zhang Y; Lu Y
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2012 Dec; 29(6):1150-5. PubMed ID: 23469547
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.